Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative ...

Eli Lilly said on Wednesday patients on obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Eli Lillys Zepbound has outperformed Novo Nordisks Wegovy in a recent clinical trial, with patients losing more weight on ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

The connection between weight loss medications and addiction reduction represents a potentially transformative discovery in ...